Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Breast Cancer

  Free Subscription


29.05.2017

1 Am J Clin Oncol
1 Am J Epidemiol
1 Ann Surg
3 BMC Cancer
1 BMJ
2 Br J Cancer
2 Breast Cancer
4 Breast Cancer Res
5 Breast Cancer Res Treat
2 Cancer
1 Carcinogenesis
3 Clin Breast Cancer
3 Clin Cancer Res
1 Curr Treat Options Oncol
1 Eur J Cancer
1 Eur J Surg Oncol
1 Exp Cell Res
1 Int J Cancer
1 Int J Oncol
2 J Clin Oncol
1 J Natl Cancer Inst
3 Oncol Rep
5 PLoS One


  Retrieve available abstracts of this week’s articles:
HTML format
Text format
 
 
Single Articles


    Am J Clin Oncol

  1. WITTAYANUKORN S, Qian J, Westrick SC, Billor N, et al
    Prevention of Trastuzumab and Anthracycline-induced Cardiotoxicity Using Angiotensin-converting Enzyme Inhibitors or beta-blockers in Older Adults With Breast Cancer.
    Am J Clin Oncol. 2017 May 23. doi: 10.1097/COC.0000000000000389.
    PubMed     Text format     Abstract available


    Am J Epidemiol

  2. WEGRZYN LR, Tamimi RM, Rosner BA, Brown SB, et al
    ROTATING NIGHT SHIFT WORK AND RISK OF BREAST CANCER IN THE NURSES' HEALTH STUDIES.
    Am J Epidemiol. 2017 May 24. doi: 10.1093.
    PubMed     Text format     Abstract available


    Ann Surg

  3. KUERER HM, Rauch GM, Krishnamurthy S, Adrada BE, et al
    A Clinical Feasibility Trial for Identification of Exceptional Responders in Whom Breast Cancer Surgery Can Be Eliminated Following Neoadjuvant Systemic Therapy.
    Ann Surg. 2017 May 25. doi: 10.1097/SLA.0000000000002313.
    PubMed     Text format     Abstract available


    BMC Cancer

  4. WILLIAMS V, Grosset AA, Zamorano Cuervo N, St-Pierre Y, et al
    Detection of IKKepsilon by immunohistochemistry in primary breast cancer: association with EGFR expression and absence of lymph node metastasis.
    BMC Cancer. 2017;17:356.
    PubMed     Text format     Abstract available

  5. WANG F, Tse LA, Chan WC, Kwok CC, et al
    Disparities of time trends and birth cohort effects on invasive breast cancer incidence in Shanghai and Hong Kong pre- and post-menopausal women.
    BMC Cancer. 2017;17:362.
    PubMed     Text format     Abstract available

  6. KUROZUMI S, Matsumoto H, Hayashi Y, Tozuka K, et al
    Power of PgR expression as a prognostic factor for ER-positive/HER2-negative breast cancer patients at intermediate risk classified by the Ki67 labeling index.
    BMC Cancer. 2017;17:354.
    PubMed     Text format     Abstract available


    BMJ

  7. TWISSELMANN B
    Through the Microscope: Chelsea garden inspired by breast cancer research.
    BMJ. 2017;357:j2519.
    PubMed     Text format    


    Br J Cancer

  8. MANDL MM, Zhang S, Ulrich M, Schmoeckel E, et al
    Inhibition of Cdk5 induces cell death of tumor-initiating cells.
    Br J Cancer. 2017;116:912-922.
    PubMed     Text format     Abstract available

  9. BRESLIN S, Lowry MC, O'Driscoll L
    Neratinib resistance and cross-resistance to other HER2-targeted drugs due to increased activity of metabolism enzyme cytochrome P4503A4.
    Br J Cancer. 2017;116:620-625.
    PubMed     Text format     Abstract available


    Breast Cancer

  10. MATSUDA N, Kida K, Ohde S, Suzuki K, et al
    Change in sonographic brightness can predict pathological response of triple-negative breast cancer to neoadjuvant chemotherapy.
    Breast Cancer. 2017 May 23. doi: 10.1007/s12282-017-0782.
    PubMed     Text format     Abstract available

  11. MIZOTA Y, Ohashi Y, Iwase T, Iwata H, et al
    Rainbow of KIBOU (ROK) study: a Breast Cancer Survivor Cohort in Japan.
    Breast Cancer. 2017 May 25. doi: 10.1007/s12282-017-0784.
    PubMed     Text format     Abstract available


    Breast Cancer Res

  12. GUO C, Sung H, Zheng S, Guida J, et al
    Age-related terminal duct lobular unit involution in benign tissues from Chinese breast cancer patients with luminal and triple-negative tumors.
    Breast Cancer Res. 2017;19:61.
    PubMed     Text format     Abstract available

  13. BAHREINI A, Li Z, Wang P, Levine KM, et al
    Mutation site and context dependent effects of ESR1 mutation in genome-edited breast cancer cell models.
    Breast Cancer Res. 2017;19:60.
    PubMed     Text format     Abstract available

  14. ST JOHN ER, Balog J, McKenzie JS, Rossi M, et al
    Rapid evaporative ionisation mass spectrometry of electrosurgical vapours for the identification of breast pathology: towards an intelligent knife for breast cancer surgery.
    Breast Cancer Res. 2017;19:59.
    PubMed     Text format     Abstract available

  15. CANDIDO DOS REIS FJ, Wishart GC, Dicks EM, Greenberg D, et al
    An updated PREDICT breast cancer prognostication and treatment benefit prediction model with independent validation.
    Breast Cancer Res. 2017;19:58.
    PubMed     Text format     Abstract available


    Breast Cancer Res Treat

  16. ROSELAND ME, Schwartz K, Ruterbusch JJ, Lamerato L, et al
    Influence of clinical, societal, and treatment variables on racial differences in ER-/PR- breast cancer survival.
    Breast Cancer Res Treat. 2017 May 25. doi: 10.1007/s10549-017-4300.
    PubMed     Text format     Abstract available

  17. ELLEGAARD MB, Grau C, Zachariae R, Jensen AB, et al
    Women with breast cancer report substantially more disease- and treatment-related side or late effects than registered by clinical oncologists: a cross-sectional study of a standard follow-up program in an oncological department.
    Breast Cancer Res Treat. 2017 May 23. doi: 10.1007/s10549-017-4301.
    PubMed     Text format     Abstract available

  18. KOPANS DB
    The Canadian National Breast Screening Studies are compromised and their results are unreliable. They should not factor into decisions about breast cancer screening.
    Breast Cancer Res Treat. 2017 May 20. doi: 10.1007/s10549-017-4302.
    PubMed     Text format     Abstract available

  19. EDWARDS MJ, Campbell ID, Lawrenson RA, Kuper-Hommel MJ, et al
    Influence of comorbidity on chemotherapy use for early breast cancer: systematic review and meta-analysis.
    Breast Cancer Res Treat. 2017 May 20. doi: 10.1007/s10549-017-4295.
    PubMed     Text format     Abstract available

  20. KELKAR MG, Thakur B, Derle A, Chatterjee S, et al
    Tumor suppressor protein p53 exerts negative transcriptional regulation on human sodium iodide symporter gene expression in breast cancer.
    Breast Cancer Res Treat. 2017 May 20. doi: 10.1007/s10549-017-4297.
    PubMed     Text format     Abstract available


    Cancer

  21. KOROUKIAN SM, Bakaki PM, Htoo PT, Han X, et al
    The Breast and Cervical Cancer Early Detection Program, Medicaid, and breast cancer outcomes among Ohio's underserved women.
    Cancer. 2017 May 23. doi: 10.1002/cncr.30720.
    PubMed     Text format     Abstract available

  22. PRINTZ C
    High-risk patients with breast cancer may not receive genetic testing.
    Cancer. 2017;123:1887.
    PubMed     Text format    


    Carcinogenesis

  23. AGUDO A, Peluso M, Munnia A, Lujan-Barroso L, et al
    Aromatic DNA adducts and breast cancer risk: a case-cohort study within the EPIC-Spain.
    Carcinogenesis. 2017 May 23. doi: 10.1093.
    PubMed     Text format     Abstract available


    Clin Breast Cancer

  24. HERMEL DJ, Wood ME, Chun J, Rounds T, et al
    Multi-institutional Evaluation of Women at High Risk of Developing Breast Cancer.
    Clin Breast Cancer. 2017 Apr 14. pii: S1526-8209(16)30264.
    PubMed     Text format     Abstract available

  25. AMORNSUPAK K, Jamjuntra P, Warnnissorn M, O-Charoenrat P, et al
    High ASMA+ Fibroblasts and Low Cytoplasmic HMGB1+ Breast Cancer Cells Predict Poor Prognosis.
    Clin Breast Cancer. 2017 Apr 21. pii: S1526-8209(16)30580.
    PubMed     Text format     Abstract available

  26. EL ZEIN D, Hughes M, Kumar S, Peng X, et al
    Metaplastic Carcinoma of the Breast Is More Aggressive Than Triple-negative Breast Cancer: A Study From a Single Institution and Review of Literature.
    Clin Breast Cancer. 2017 Apr 26. pii: S1526-8209(16)30556.
    PubMed     Text format     Abstract available


    Clin Cancer Res

  27. REINHOLZ MM, Chen B, Dueck AC, Tenner K, et al
    IGF1R Protein Expression Is Not Associated with Differential Benefit to Concurrent Trastuzumab in Early-Stage HER2+ Breast Cancer from the North Central Cancer Treatment Group (Alliance) Adjuvant Trastuzumab Trial N9831.
    Clin Cancer Res. 2017 May 22. doi: 10.1158/1078-0432.CCR-15-0574.
    PubMed     Text format     Abstract available

  28. SCHOTT AF, Goldstein L, Cristofanilli M, Ruffini PA, et al
    Phase Ib pilot study to evaluate reparixin in combination with weekly paclitaxel in patients with HER-2 negative metastatic breast cancer (MBC).
    Clin Cancer Res. 2017 May 24. pii: clincanres.2748.2016.
    PubMed     Text format     Abstract available

  29. DICKLER MN, Tolaney S, Rugo HS, Cortes J, et al
    MONARCH 1, a phase 2 study of abemaciclib, a CDK4 and CDK6 inhibitor, as a single agent, in patients with refractory HR+/HER2- metastatic breast cancer.
    Clin Cancer Res. 2017 May 22. pii: clincanres.0754.2017.
    PubMed     Text format     Abstract available


    Curr Treat Options Oncol

  30. MANSOUR M, Teo ZL, Luen SJ, Loi S, et al
    Advancing Immunotherapy in Metastatic Breast Cancer.
    Curr Treat Options Oncol. 2017;18:35.
    PubMed     Text format     Abstract available


    Eur J Cancer

  31. LYNGE E, Beau AB, Christiansen P, von Euler-Chelpin M, et al
    Overdiagnosis in breast cancer screening: The impact of study design and calculations.
    Eur J Cancer. 2017;80:26-29.
    PubMed     Text format     Abstract available


    Eur J Surg Oncol

  32. HOUVENAEGHEL G, Boher JM, Michel V, Bannier M, et al
    Survival after breast cancer local recurrence according to therapeutic strategies.
    Eur J Surg Oncol. 2017 May 4. pii: S0748-7983(17)30448.
    PubMed     Text format     Abstract available


    Exp Cell Res

  33. YI Z, Yang D, Liao X, Guo F, et al
    PSME3 induces epithelial-mesenchymal transition with inducing the expression of CSC markers and immunosuppression in breast cancer.
    Exp Cell Res. 2017 May 18. pii: S0014-4827(17)30296.
    PubMed     Text format     Abstract available


    Int J Cancer

  34. VAN DEN ENDE C, Oordt-Speets AM, Vroling H, van Agt HME, et al
    Benefits and harms of breast cancer screening with mammography in women aged 40-49 years: A systematic review.
    Int J Cancer. 2017 May 19. doi: 10.1002/ijc.30794.
    PubMed     Text format     Abstract available


    Int J Oncol

  35. LIANG N, Li Y, Chung HY
    Two natural eudesmane-type sesquiterpenes from Laggera alata inhibit angiogenesis and suppress breast cancer cell migration through VEGF- and Angiopoietin 2-mediated signaling pathways.
    Int J Oncol. 2017 May 17. doi: 10.3892/ijo.2017.4004.
    PubMed     Text format     Abstract available


    J Clin Oncol

  36. VENTZ S, Alexander BM, Parmigiani G, Gelber RD, et al
    Designing Clinical Trials That Accept New Arms: An Example in Metastatic Breast Cancer.
    J Clin Oncol. 2017 May 22:JCO2016701169. doi: 10.1200/JCO.2016.70.1169.
    PubMed     Text format     Abstract available

  37. BEALE DJ
    Conclusion Based on Insufficient Data in Study of Protein Intake Association With Breast Cancer Survival.
    J Clin Oncol. 2017;35:1857.
    PubMed     Text format    


    J Natl Cancer Inst

  38. KUCHENBAECKER KB, McGuffog L, Barrowdale D, Lee A, et al
    Evaluation of Polygenic Risk Scores for Breast and Ovarian Cancer Risk Prediction in BRCA1 and BRCA2 Mutation Carriers.
    J Natl Cancer Inst. 2017;109.
    PubMed     Text format     Abstract available


    Oncol Rep

  39. WANG Y, Peng Z, Meng R, Tao T, et al
    NHERF1 inhibits proliferation of triple-negative breast cancer cells by suppressing GPER signaling.
    Oncol Rep. 2017 May 18. doi: 10.3892/or.2017.5649.
    PubMed     Text format     Abstract available

  40. LI X, Chen W, Wang H, Wei Q, et al
    Amplification and the clinical significance of circulating cell-free DNA of PVT1 in breast cancer.
    Oncol Rep. 2017 May 18. doi: 10.3892/or.2017.5650.
    PubMed     Text format     Abstract available

  41. SHEN SQ, Huang LS, Xiao XL, Zhu XF, et al
    miR-204 regulates the biological behavior of breast cancer MCF-7 cells by directly targeting FOXA1.
    Oncol Rep. 2017 May 16. doi: 10.3892/or.2017.5644.
    PubMed     Text format     Abstract available


    PLoS One

  42. MISHRA AK, Parish CR, Wong ML, Licinio J, et al
    Leptin signals via TGFB1 to promote metastatic potential and stemness in breast cancer.
    PLoS One. 2017;12:e0178454.
    PubMed     Text format     Abstract available

  43. EVERS C, Fischer C, Dikow N, Schott S, et al
    Familial breast cancer: Genetic counseling over time, including patients expectations and initiators considering the Angelina Jolie effect.
    PLoS One. 2017;12:e0177893.
    PubMed     Text format     Abstract available

  44. CHOI Y, Kim SH, Youn IK, Kang BJ, et al
    Rim sign and histogram analysis of apparent diffusion coefficient values on diffusion-weighted MRI in triple-negative breast cancer: Comparison with ER-positive subtype.
    PLoS One. 2017;12:e0177903.
    PubMed     Text format     Abstract available

  45. LIU Z, He K, Ma Q, Yu Q, et al
    Autophagy inhibitor facilitates gefitinib sensitivity in vitro and in vivo by activating mitochondrial apoptosis in triple negative breast cancer.
    PLoS One. 2017;12:e0177694.
    PubMed     Text format     Abstract available

  46. SCHMITZ AMT, Teixeira SC, Pengel KE, Loo CE, et al
    Monitoring tumor response to neoadjuvant chemotherapy using MRI and 18F-FDG PET/CT in breast cancer subtypes.
    PLoS One. 2017;12:e0176782.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Breast Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: